Skip to content

Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee

Knee Injuries | Knee Discomfort | Cartilage Injury | Cartilage Disease

Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the knee with microfracture plus the Chondro-Gide® ACC is non-inferior to treatment of small chondral lesions treated with microfracture alone.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 55

Participation Criteria

Inclusion Criteria:

1. Signed written informed consent
2. One symptomatic knee with cartilage defect on the medial femoral condyle, lateral femoral condyle, or trochlea, identified MRI or arthroscopy
3. Between 18 and 55 years of age
4. Subject is willing and able to comply with all study procedures, including visits, diagnostic procedures, and the rehabilitation protocol

Exclusion Criteria:

1. BMI ≥ 30 kg/m2
2. Symptomatic contralateral knee
3. Diagnosis of radiographic osteoarthritis with Kellgren-Lawrence grade 3 or more
4. Prior surgical treatment of the cartilage using microfracture, mosaicplasty, or autologous chondrocyte implantation (debridement and lavage are acceptable if the procedure was at least 3 months prior to enrollment)
5. Patella dysplasia
6. Chronic inflammatory arthritis or infectious arthritis
7. History of autoimmune disease or immunodeficiency
8. History of connective tissue disease
9. Intra-articular steroid use within the 3 months prior to enrollment
10. Other intra-articular injections (e.g. hyaluronic acid) within 3 months prior to enrollment
11. The patient is currently being treated with radiation, chemotherapy, immunosuppression or systemic steroid therapy with a dose equivalent to more than 5 mg prednisolone
12. Pregnancy or lack of adequate contraceptives if a female of child-bearing potential
13. Enrolled in another study, involved in the study (as a researcher/investigator/sponsor), or relative of someone directly involved in the study
14. Active infection of the index knee
15. Previous diagnosis of osteoporosis as diagnosed by DEXA, bone densitometry or CT scan
16. Any disorder or impairment that would interfere with evaluation of outcomes measures, such as neurological, degenerative muscular, psychiatric, or cognitive conditions
17. History or current substance or alcohol abuse as defined by the DSM-V
18. Any other medical condition that the investigator determines would interfere with the validity of the study
19. Known allergy to porcine collagen
20. Symptom duration greater than 36 months

Study Location

Fraser Orthopaedic Institute
Fraser Orthopaedic Institute
New Westminster, British Columbia
Canada

Contact Study Team

Primary Contact

Kyrsten Payne

[email protected]
Sunnybrook Research Institute (SRI)
Sunnybrook Research Institute (SRI)
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Meghan Ryan

[email protected]
St. Joseph's Healthcare Hamilton
St. Joseph's Healthcare Hamilton
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Breanne Flood

[email protected]
(289) 237-7380
University of Calgary
University of Calgary
Calgary, CGY
Canada

Contact Study Team

Primary Contact

Jolene Allan

[email protected]
University of Toronto Orthopaedics
University of Toronto Orthopaedics
Toronto, TOR
Canada

Contact Study Team

Primary Contact

Ananya Pathak

[email protected]
Hamilton Health Sciences
Hamilton Health Sciences
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Nicole Simunovic

[email protected]
Study Sponsored By
Geistlich Pharma AG
Participants Required
More Information
Study ID: NCT04537013